Compare Figma Inc. Class A Common Stock (FIG) vs Vaxcyte Inc. Common Stock (PCVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figma Inc. Class A Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? Figma Inc. Class A Common Stock trades at $21.24 (market cap $11.60B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Figma Inc. Class A Common Stock and Vaxcyte Inc. Common Stock are close in size by market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Figma Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Figma Inc. Class A Common Stock for 0 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| FIG | PCVX | |
|---|---|---|
Market Cap | $11.60B | $10.51B |
Volume | 12,281,013 | 2,644,694 |
Sector | Technology | Health |
52-Week High | $63.82 | $73.82 |
52-Week Low | $16.84 | $40.32 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $10.00B | $9.14B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Figma Inc. Class A Common Stock
Figma, Inc. is a US software company that operates a collaborative interface design and product development platform used by design and engineering teams to create, prototype, and build digital products.
Read more on FIG →About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →
